Iron, oxidative stress, and clinical outcomes

Pediatric Nephrology

Volumn 23, Issue 8, 2008, Pages 1195-1199

  Agarwal, Rajiv ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Iron; Oxidative stress; Proteinuria; Randomized trial

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; DEFEROXAMINE; ERYTHROPOIETIN; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS GLUCONATE; FERROUS SULFATE; GLUTATHIONE; IRON; IRON DERIVATIVE; IRON DEXTRAN; IRON SACCHARATE; LIPID PEROXIDE; OLIGOSACCHARIDE;

ALBUMINURIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CELL PROTECTION; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPOTENSION; INFLAMMATION; IRON DEFICIENCY ANEMIA; IRON TRANSPORT; KIDNEY FIBROSIS; LIPID PEROXIDATION; MORTALITY; MYALGIA; NAUSEA; NEPHROTIC SYNDROME; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RISK BENEFIT ANALYSIS; SEPSIS; SIDE EFFECT; TASTE DISORDER; VOMITING;

ANIMALS; CHILD; ERYTHROPOIETIN; HUMANS; IRON; OXIDATIVE STRESS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 46949110940     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-007-0673-1     Document Type: Editorial

References (41)

1. Horl WH (2007) Iron therapy for renal anemia: How much needed, how much harmful? Pediatr Nephrol 22:480-489
2. Zager RA, Johnson AC, Hanson SY, Wasse H (2002) Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40:90-103
3. Zager RA, Johnson AC, Hanson SY (2004) Parenteral iron nephrotoxicity: Potential mechanisms and consequences. Kidney Int 66:144-156
4. Zager RA, Johnson AC, Hanson SY (2004) Proximal tubular cytochrome c efflux: Determinant, and potential marker, of mitochondrial injury. Kidney Int 65:2123-2134
5. Agarwal R, Campbell RC, Warnock DG (2004) Oxidative stress in hypertension and chronic kidney disease: Role of angiotensin II. Semin Nephrol 24:101-114
6. Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJ (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32[Suppl 1]:9-16
7. Agarwal R, Vasavada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-2289
8. Agarwal R (2005) On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. Am J Physiol Renal Physiol 288:F265-F271
9. Agarwal R (2006) Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 69:1259-1263
10. Leehey DJ, Palubiak DJ, Chebrolu S, Agarwal R (2005) Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: A pilot study. Nephrol Dial Transplant 20:135-140
11. Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR (2007) Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 72:638-642
12. Lim PS, Wei YH, Yu YL, Kho B (1999) Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14:2680-2687
13. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM (2000) Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 11:539-549
14. Salahudeen AK, Oliver B, Bower JD, Roberts LS 2nd (2001) Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 60:1525-1531
15. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM (2002) Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217
16. Anraku M, Kitamura K, Shinohara A, Adachi M, Suenga A, Maruyama T, Miyanaka K, Miyoshi T, Shiraishi N, Nonoguchi H, Otagiri M, Tomita K (2004) Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 66:841-848
17. Attallah N, Osman-Malik Y, Frinak S, Besarab A (2006) Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47:644-654
18. Eiselt J, Racek J, Opatrny K Jr, Trefil L, Stehlík P (2006) The effect of intravenous iron on oxidative stress in hemodialysis patients at various levels of vitamin C. Blood Purif 24:531-537
19. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B (2002) Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 346:913-923
20. Haugen E, Nath KA (1999) The involvement of oxidative stress in the progression of renal injury. Blood Purif 17:58-65
21. Klahr S (1997) Oxygen radicals and renal diseases. Miner Electrolyte Metab 23:140-143
22. Shah SV (2001) Role of iron in progressive renal disease. Am J Kidney Dis 37:S30-S33
23. Nath KA, Croatt AJ, Haggard JJ, Grande JP (2000) Renal response to repetitive exposure to heme proteins: Chronic injury induced by an acute insult. Kidney Int 57:2423-2433
24. Johnson RJ, Couser WG, Chi EY, Adler S, Klebanoff SJ (1987) New mechanism for glomerular injury. Myeloperoxidase-hydrogen peroxide-halide system. J Clin Invest 79:1379-1387
25. Gailit J, Colflesh D, Rabiner I, Simone J, Goligorsky MS (1993) Redistribution and dysfunction of integrins in cultured renal epithelial cells exposed to oxidative stress. Am J Physiol 264:F149-F157
26. Shah SV (1988) Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats. Am J Physiol 254:F337-F344
27. Alfrey AC, Froment DH, Hammond WS (1989) Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 36:753-759
28. Nankivell BJ, Boadle RA, Harris DC (1992) Iron accumulation in human chronic renal disease. Am J Kidney Dis 20:580-584
29. Sato K, Shiraki M (1998) Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy. Endocr J 45:431-439
30. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS (2000) Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356:1213-1218
31. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W (2003) The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 107:992-995
32. Kletzmayr J, Horl WH (2002) Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 17[Suppl 2]:25-29
33. Kirk EA, Heinecke JW, LeBoeuf RC (2001) Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 107:1545-1553
34. Stoves J, Inglis H, Newstead CG (2001) A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16:967-974
35. Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G (2003) Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 51:170-174
36. Charytan C, Qunibi W, Bailie GR (2005) Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100:c55-c62
37. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S; United States Iron Sucrose (Venofer) Clinical Trials Group (2005) A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68:2846-2856
38. Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A (2006) A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 26:445-454
39. Agarwal R (2007) Nonhematological benefits of iron. Am J Nephrol 27:565-571
40. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085-2098
41. Zager RA, Johnson AC, Hanson SY (2004) Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 65:2108-2112